UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (1), p.329-337

2009

Volltextzugriff (PDF)

Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines

PloS one, 2013-12, Vol.8 (12), p.e80060-e80060

2013

Volltextzugriff (PDF)

E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase

Cancer research (Chicago, Ill.), 2007-04, Vol.67 (7), p.3094-3105

2007

Volltextzugriff (PDF)

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

Pediatric blood & cancer, 2008-01, Vol.50 (1), p.37-45

2008

Volltextzugriff (PDF)

Study Design of an Open-Label, Single-Arm, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in Adult Patients with Transplant-Associated Thrombotic Microangiopathy

Blood, 2019-11, Vol.134 (Supplement_1), p.3257-3257

2019

Volltextzugriff (PDF)

Cdc6 knockdown inhibits human neuroblastoma cell proliferation

Molecular and cellular biochemistry, 2008-04, Vol.311 (1-2), p.189-197

2008

Volltextzugriff (PDF)

Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p53

Clinical cancer research, 2003-08, Vol.9 (9), p.3492-3502

2003

Volltextzugriff (PDF)

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood, 2023-11, Vol.142 (Supplement 1), p.1537-1537

2023

Volltextzugriff (PDF)

Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer

Clinical cancer research, 2024-07, Vol.30 (14), p.2945-2953

2024

Volltextzugriff (PDF)

Assessing combinations of cytotoxic agents using leukemia cell lines

Current drug targets, 2007-06, Vol.8 (6), p.765-771

2007

Volltextzugriff (PDF)

Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5510-5510

2021

Volltextzugriff (PDF)

Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53

Molecular cancer therapeutics, 2010-12, Vol.9 (12), p.3289-3301

2010

Volltextzugriff (PDF)

National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing

Pediatric blood & cancer, 2011-02, Vol.56 (2), p.239-249

2011

Volltextzugriff (PDF)

Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide

JNCI : Journal of the National Cancer Institute, 2007-07, Vol.99 (14), p.1107-1119

2007

Volltextzugriff (PDF)

IS O-06. Interleukin-6 Promotes Proliferation and Survival of Neuroblastoma cells in the Bone Marrow Microenvironment

Journal of the Japanese Society of Pediatric Surgeons, 2009, Vol.45 (3), p.458-458

2009

Volltextzugriff (PDF)

Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines

Cancer research (Chicago, Ill.), 2001-08, Vol.61 (16), p.6185-6193

2001

Volltextzugriff (PDF)

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program

Pediatric blood & cancer, 2009-09, Vol.53 (3), p.505-508

2009

Volltextzugriff (PDF)

Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy

Cancer research (Chicago, Ill.), 1998-12, Vol.58 (23), p.5396-5405

1998

Volltextzugriff (PDF)

DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy

Methods in molecular medicine, 2005, Vol.110, p.139

2005

Volltextzugriff (PDF)

Interieukin-6 in the Bone Marrow Microenvironment Promotes the Growth and Survival of Neuroblastoma Cells

Cancer research (Chicago, Ill.), 2009, Vol.69 (1), p.329-337

2009

Volltextzugriff (PDF)

Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine

Cancer research (Chicago, Ill.), 2003-04, Vol.63 (7), p.1520-1526

2003

Volltextzugriff (PDF)

Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody

Cytometry. Part A, 2007-11, Vol.71A (11), p.951-960

2007

Volltextzugriff (PDF)

In vitro testing of chemosensitivity in physiological hypoxia

Methods in molecular medicine, 2005, Vol.110, p.87

2005

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells

Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines

E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

Study Design of an Open-Label, Single-Arm, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Defibrotide in Adult Patients with Transplant-Associated Thrombotic Microangiopathy

Cdc6 knockdown inhibits human neuroblastoma cell proliferation

Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p53

Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer

Assessing combinations of cytotoxic agents using leukemia cell lines

Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer

Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53

National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide

IS O-06. Interleukin-6 Promotes Proliferation and Survival of Neuroblastoma cells in the Bone Marrow Microenvironment

Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program

Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy

DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy

Interieukin-6 in the Bone Marrow Microenvironment Promotes the Growth and Survival of Neuroblastoma Cells

Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine

Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody

In vitro testing of chemosensitivity in physiological hypoxia

Suchergebnisse filtern